Computational analysis of human N-acetylgalactosamine-6-sulfate sulfatase enzyme: an update in genotype–phenotype correlation for Morquio A

被引:0
|
作者
Sergio Olarte-Avellaneda
Alexander Rodríguez-López
Carlos Javier Alméciga-Díaz
Luis Alejandro Barrera
机构
[1] Universidad Colegio Mayor de Cundinamarca,Clinical Bacteriology Program, School of Health Sciences
[2] Pontificia Universidad Javeriana,Proteins Expression and Purification Laboratory, Institute for the Study of Inborn Errors of Metabolism, School of Sciences
来源
Molecular Biology Reports | 2014年 / 41卷
关键词
MPS IV A; GALNS; Keratan sulfate; Chondroitin-6-sulfate; Molecular modeling; Computational molecular docking;
D O I
暂无
中图分类号
学科分类号
摘要
Mucopolysaccharidosis IV A (MPS IV A) is a lysosomal storage disease produced by the deficiency of N-acetylgalactosamine-6-sulfate sulfatase (GALNS) enzyme. Although genotype–phenotype correlations have been reported, these approaches have not enabled to establish a complete genotype–phenotype correlation, and they have not considered a ligand–enzyme interaction. In this study, we expanded the in silico evaluation of GALNS mutations by using several bioinformatics tools. Tertiary GALNS structure was modeled and used for molecular docking against galactose-6-sulfate, N-acetylgalactosamine-6-sulfate, keratan sulfate, chondroitin-6-sulfate, and the artificial substrate 4-methylumbelliferyl-β-d-galactopyranoside-6-sulfate. Furthermore, we considered the evolutionary residue conservation, change conservativeness, position within GALNS structure, and the impact of amino acid substitution on the structure and function of GALNS. Molecular docking showed that amino acids involved in ligand interaction correlated with those observed in other human sulfatases, and mutations within the active cavity reduced affinity of all evaluated ligands. Combination of several bioinformatics approaches allowed to explaine 90 % of the missense mutations affecting GALNS, and the prediction of the phenotype for another 21 missense mutations. In summary, we have shown for the first time a docking evaluation of natural and artificial ligands for human GALNS, and proposed an update in genotype–phenotype correlation for Morquio A, based on the use of multiple parameters to predict the disease severity.
引用
收藏
页码:7073 / 7088
页数:15
相关论文
共 50 条
  • [31] Characterization of Human Recombinant N-Acetylgalactosamine-6-Sulfate Sulfatase Produced in Pichia pastoris as Potential Enzyme for Mucopolysaccharidosis IVA Treatment
    Rodriguez-Lopez, Alexander
    Pimentel-Vera, Luisa N.
    Espejo-Mojica, Angela J.
    Van Hecke, Annelies
    Tiels, Petra
    Tomatsu, Shunji
    Callewaert, Nico
    Almeciga-Diaz, Carlos J.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 108 (08) : 2534 - 2541
  • [32] Human recombinant N-acetylgalactosamine-6-sulfate sulfatase (GALNS) produced in a glycoengineered Escherichia coli strain
    Almeciga-Diaz, Carlos J.
    Pimentel-Vera, Luisa N.
    Rodriguez-Lopez, Alexander
    Espejo-Mojica, Angela
    Ramirez, Aura M.
    Cardona, Carolina
    Reyes, Luis H.
    DeLisa, Matthew P.
    Sanchez, Oscar F.
    MOLECULAR GENETICS AND METABOLISM, 2017, 120 (1-2) : S20 - S20
  • [33] Recombinant human N-acetylgalactosamine-6-sulfate sulfatase (GALNS) produced in the methylotrophic yeast Pichia pastoris
    Rodriguez-Lopez, Alexander
    Almeciga-Diaz, Carlos J.
    Sanchez, Jhonnathan
    Moreno, Jefferson
    Beltran, Laura
    Diaz, Dennis
    Pardo, Andrea
    Maria Ramirez, Aura
    Espejo-Mojica, Angela J.
    Pimentel, Luisa
    Barrera, Luis A.
    SCIENTIFIC REPORTS, 2016, 6
  • [34] Mouse model of N-acetylgalactosamine-6-sulfate sulfatase deficiency (Galns-/-) produced by targeted disruption of the gene defective in Morquio A disease
    Tomatsu, S
    Orii, KO
    Vogler, C
    Nakayama, J
    Levy, B
    Grubb, JH
    Gutierrez, MA
    Shim, S
    Yamaguchi, S
    Nishioka, T
    Montaño, AM
    Noguchi, A
    Orii, T
    Kondo, N
    Sly, WS
    HUMAN MOLECULAR GENETICS, 2003, 12 (24) : 3349 - 3358
  • [35] MUCOPOLYSACCHARIDOSIS IVA - SCREENING AND IDENTIFICATION OF MUTATIONS OF THE N-ACETYLGALACTOSAMINE-6-SULFATE SULFATASE GENE
    OGAWA, T
    TOMATSU, S
    FUKUDA, S
    YAMAGISHI, A
    REZVI, GMM
    SUKEGAWA, K
    KONDO, N
    SUZUKI, Y
    SHIMOZAWA, N
    ORII, T
    HUMAN MOLECULAR GENETICS, 1995, 4 (03) : 341 - 349
  • [36] HUMAN N-ACETYLGALACTOSAMINE-6-SULFATE SULFATASE - MOLECULAR-CLONING AND STRUCTURAL-ANALYSIS OF THE GENE AND 5' FLANKING REGION
    NAKASHIMA, Y
    TOMATSU, S
    HORI, T
    FUKUDA, S
    SUKEGAWA, K
    ORII, T
    AMERICAN JOURNAL OF HUMAN GENETICS, 1993, 53 (03) : 933 - 933
  • [37] Cell uptake evaluation of human recombinant N-acetylgalactosamine-6-sulfate sulfatase (GALNS) produced in Pichia pastoris
    Rodriguez-Lopez, Alexander
    Cardona, Carolina
    Pimentel, Natalia
    Espejo-Mojica, Angela J.
    Almeciga-Diaz, Carlos J.
    MOLECULAR GENETICS AND METABOLISM, 2017, 120 (1-2) : S116 - S116
  • [38] DIFFERENT PROPERTIES OF RESIDUAL N-ACETYLGALACTOSAMINE-6-SULFATE SULFATASE IN FIBROBLASTS FROM PATIENTS WITH MILD AND SEVERE FORMS OF MORQUIO DISEASE TYPE-A
    GLOSSL, J
    MAROTEAUX, P
    DINATALE, P
    KRESSE, H
    PEDIATRIC RESEARCH, 1981, 15 (06) : 976 - 978
  • [39] Diagnosing Mucopolysaccharidosis type IV a by the fluorometric assay of N-Acetylgalactosamine-6-sulfate sulfatase activity
    Shams S.
    Barazandeh Tehrani M.
    Civallero G.
    Minookherad K.
    Giugliani R.
    Setoodeh A.
    Ashtiani M.T.H.
    Journal of Diabetes & Metabolic Disorders, 16 (1):
  • [40] Effect of 'attenuated' mutations in mucopolysaccharidosis IVA on molecular phenotypes of N-acetylgalactosamine-6-sulfate sulfatase
    Montano, A. M.
    Sukegawa, K.
    Kato, Z.
    Carrozzo, R.
    Di Natale, P.
    Christensen, E.
    Orii, K. O.
    Orii, T.
    Kondo, N.
    Tomatsu, S.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2007, 30 (05) : 758 - 767